MK-7 Vitamin K2 Composition for Warfarin-Linked Tissue Calcification
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for new clinical approaches to prevent and/or reverse pathologic calcification in subjects with diabetes, chronic kidney disease, end stage renal disease, and subjects receiving anticoagulant and/or statin therapy, as existing treatments disrupt Vitamin K regulation leading to tissue calcification.
Innovation Solution
Administering high doses of menaquinone-7 (MK-7) and/or menaquinol-7 (MKH2-7) in pharmaceutical compositions to increase Vitamin K-dependent protein carboxylation, thereby preventing or reversing tissue calcification.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing treatments (warfarin-based anticoagulant therapy and statin therapy) are used, then coagulation control and lipid management are improved, but Vitamin K regulation is disrupted leading to tissue calcification
Solution Approach 1:
The patent introduces MK-7 as an intermediary substance that mediates between the harmful effects of warfarin/statin therapy and the need for Vitamin K-dependent protein carboxylation. MK-7 serves as a stable Vitamin K2 form that can replenish functional Vitamin K levels without being affected by warfarin's anticoagulant mechanism, thereby preventing tissue calcification while allowing continued use of existing treatments
Solution Approach 2:
The patent changes the Vitamin K parameter by administering high doses of MK-7 (at least 2 mg/day) to overcome the Vitamin K dysregulation caused by existing treatments. This parameter change restores the carboxylation status of Vitamin K-dependent proteins like MGP, thereby preventing pathological calcification in subjects receiving warfarin or statin therapy
2Reliability
If high doses of MK-7 and/or MKH2-7 are administered, then Vitamin K-dependent protein carboxylation is enhanced preventing tissue calcification, but dosage and formulation complexity increases
Solution Approach 1:
The patent segments the Vitamin K supplementation approach by providing specific dosage ranges (at least 2 mg/day, with embodiments ranging from 2-100 mg/day) tailored to different subject conditions such as CKD, ESRD, and those on warfarin or statin therapy. This segmentation allows clinicians to select appropriate doses based on individual patient needs, managing complexity through structured dosing guidelines
Solution Approach 2:
The patent creates a universal pharmaceutical composition that can be used across multiple patient populations (subjects with diabetes, CKD, ESRD, and those receiving anticoagulant or statin therapy). The composition serves multiple functions: replenishing Vitamin K, enhancing protein carboxylation, preventing calcification, and potentially improving outcomes in various disease states, thereby simplifying the approach despite the diverse patient群体
3Object-affected harmful factors
If Vitamin K is depleted due to uremia or hemodialysis, then calcium-phosphate crystal formation is unchecked causing vascular calcification, but kidney function cannot be restored
Solution Approach 1:
The patent uses MK-7 as an intermediary to bypass the dysfunctional kidney system. Instead of attempting to restore kidney function, the treatment directly supplements Vitamin K2 to ensure adequate carboxylation of Vitamin K-dependent proteins, thereby preventing calcification despite the ongoing kidney dysfunction and uremia
Solution Approach 2:
The patent applies preliminary action by administering MK-7 before pathological calcification can progress further in subjects with CKD and ESRD. By preemptively replenishing Vitamin K stores and enhancing carboxylation status, the treatment prevents the unchecked calcium-phosphate crystal formation that would otherwise occur due to Vitamin K depletion from uremia or hemodialysis
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The administration of MK-7 and/or MKH2-7 significantly increases serum T50 values, enhances the ratio of carboxylated to non-carboxylated Vitamin K-dependent proteins, and reduces markers of inflammation and calcification, effectively preventing or reversing tissue calcification.
Implementation Method 1
increase Vitamin K-dependent protein carboxylation
Implementation Method 2
Vitamin K is an essential enzymatic co-factor that is required for post-translational modifications of Vitamin K-dependent (VKD) proteins
Implementation Method 3
Uremia can promote the oxidation of Vitamin K hydroquinone (KH2), thereby disrupting the cyclic regeneration of Vitamin K
Implementation Method 4
reduces markers of inflammation and calcification, effectively preventing or reversing tissue calcification
Data Source
AI summary
The invention provides methods and compositions for preventing or treating (e.g., slowing the progression of, arresting, and/or reversing) tissue calcification in a subject in need thereof and, more particularly, the invention relates to methods of using menaquinone-7 (MK-7) and/or menaquinol-7 (MKH2-7) for preventing or treating (e.g., slowing the progression of, arresting, and/or reversing) tissue calcification in a subject with diabetes, chronic kidney disease, end stage renal failure, or a subject undergoing hemodialysis and/or receiving anticoagulant therapy. The invention further provides methods and compositions for reducing one or more symptoms of chronic obstructive pulmonary disorder (COPD), including using menaquinone-7 (MK-7) and/or menaquinol-7 (MKH2-7), for preventing or treating (e.g., slowing the progression of, arresting, and/or reversing) one or more symptoms of COPD.